IGF-1 marker comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-29. Numbers and descriptions here follow the published literature rather than marketing material.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
| Property | Value | Notes |
|---|---|---|
| Primary marker | Insulin-like growth factor 1 | Slow-changing integrated indicator of axis activity |
| Secondary marker | Growth hormone | Pulsatile; requires repeated or timed sampling |
| Typical analytical method | Immunoassay | Antibody-based quantification in serum |
| Common sample matrix | Serum | Collected under standardized conditions |
| Key interpretation factor | Age-stratified reference ranges | Baseline marker concentrations shift with age |
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
== History == August Troendle founded Medpace in Cincinnati, Ohio, in 1992 as Medical Research Services. Troendle first became interested in the CRO sector after working in both the regulatory and pharmaceutical area. He began his career as a reviewer with the FDA, specializing in the development of lipid lowering therapies to treat high cholesterol. With a team of industry physicians, Jonathan Issacsohn and Evan Stein completed many early studies while at Medpace and Medpace Reference Laboratories on the use of statin therapies for the treatment of hypercholesterolemia. Another Medpace physician, David Orloff was regarded as an industry opinion leader in the study of metabolic diseases – most specifically diabetes and obesity. Troendle was honored for his work as a Medpace founder in 2012 by the Cincinnati Chamber of Commerce. Medpace completed construction on a new campus in 2012 in Madisonville, a neighborhood on the eastern side of Cincinnati. The project encompassed revitalizing an urban brownfield site formerly occupied by NuTone, and creating a state of the art LEED (Leadership in Energy and Environmental Design) certified campus. In 2022, Medpace announced a $150 million capital investment to expand its headquarters in Cincinnati, Ohio, adding an estimated expansion of 1,500 new jobs. Medpace expanded internationally through several acquisitions between 2007 and 2012. It acquired the Czech Republic contract research organization Monax in 2007, followed by Switzerland-based PharmaBrains AG in 2009.
This is a list of notable women mass spectrometrists with significant scientific contribution towards advancement in theories, instrumentation and applications of mass spectrometry. The list is organized by the chemical societies and their major awards related to mass spectrometry, as well as presidency.
Modern units use a magnetic door gasket that holds the door sealed but allows it to be pushed open from the inside. This gasket was invented, developed and manufactured by Max Baermann (1903–1984) of Bergisch Gladbach/Germany. Regarding total life-cycle costs, many governments offer incentives to encourage recycling of old refrigerators. One example is the Phoenix refrigerator program launched in Australia. This government incentive picked up old refrigerators, paying their owners for "donating" the refrigerator. The refrigerator was then refurbished, with new door seals, a thorough cleaning, and the removal of items such as the cover that is strapped to the back of many older units. The resulting refrigerators, now over 10% more efficient, were then given to low-income families. The United States also has a program for collecting and replacing older, less-efficient refrigerators and other white goods. These programs seek to replace large appliances that are old and inefficient or faulty by newer, more energy-efficient appliances, to reduce the cost imposed on lower-income families, and reduce pollution caused by the older appliances.
In late 1988, tensions between the United States and Panama were extremely high with the Panamanian leader, Manuel Noriega, calling for the dissolution of the agreement that allowed the United States to have bases in his country. In December 1989 President George H. W. Bush activated the planning section for Operation Just Cause/Promote Liberty. Just Cause was the portion of the mission to depose Noriega and return Panama to democracy. Originally scheduled to begin at 0200 hrs. on 20 December, it actually kicked off at 2315 hrs when part of a Special Forces detachment that was waiting for the signal to begin was discovered above a gate above a Panamanian checkpoint. Just Cause was the first mission to have a very large contingent of Special Operations Forces on the ground. The units that were involved with the mission were as follows: Task Force Green (Delta Force), Task Force Black (7th SFG), 5th SFG, 3rd SFG, 4th PSYOP Group, the reinforced 1st Brigade of the 82nd Airborne Division, and all three battalions of the 75th Rangers, and numerous other units from other forces such as the Navy SEALs, Marine Force Recon, and Air Force Combat Control Teams. Of the 23 US troops who died in the invasion four were Navy SEALs. The invasion was successful at deposing Noriega, but led to widespread looting and lawlessness in the following weeks.
Sources: en.wikipedia.org
A series of WHO yaws control efforts, which began shortly after the creation of the WHO in 1948, succeeded in eradicating the disease locally from many countries, but have not lasted long enough to eradicate it globally. The Global Control of Treponematoses (TCP) programme by the WHO and the UNICEF was launched in 1952 and continued until 1964. A 1953 questionnaire-based estimate was that there were 50–150 million yaws cases in 90 countries. The global prevalence of yaws and the other endemic treponematoses, bejel and pinta, was reduced by the Global Control of Treponematoses (TCP) programme between 1952 and 1964 from about 50 million cases to about 2.5 million (a 95% reduction). However, "premature integration of yaws and other endemic treponematoses activities into weak primary health-care systems, and the dismantling of the vertical eradication programmes after 1964, led to the failure to finish with the remaining 5% of cases" and also led to a resurgence of yaws in the 1970s, with the largest number of case found in the Western Africa region. Following the cessation of this program, resources, attention and commitment for yaws gradually disappeared, and yaws remained at a low prevalence in parts of Asia, Africa, and the Americas with sporadic outbreaks. With few cases, mainly affecting poor, remote communities with little access to treatment, yaws became poorly known, yaws knowledge and skills died out even among health professionals, and yaws eradication was not seen as a high priority.
The Hok/sok system a post-segregational killing system of the plasmid, toxin-antitoxin system hok: encodes a toxin that kills cells without the plasmid. sok: short anti-sense RNA that inhibits hok mRNA translation in plasmid carrying cells.
== Examples == Inflammation is usually indicated by adding the suffix "itis", as shown below. However, some conditions, such as asthma and pneumonia, do not follow this convention. More examples are available at List of types of inflammation.
Sources: en.wikipedia.org
== Entry == The Clinical School was established in 1976 while construction of the new building at its present site was underway. The clinical course was restructured in 2005 with the addition of a new final year, as the clinical course had previously been less than three years in length. Before 2017, approximately half of medical students left Cambridge after the pre-clinical course as there were not enough places on the clinical course for them all; common destinations included medical schools based in Oxford, London and Manchester. From 2017, all medical students continue to study in Cambridge for the full six years provided they pass the pre-clinical component of the course. Students enter the clinical course at Cambridge following satisfactory progression during the pre-clinical component of the combined medical course or as part of the graduate course.
Carbon and carbon-rich materials have desirable properties but are nonvolatile, even at high temperatures. Consequently, pyrolysis is used to produce many kinds of carbon; these can be used for fuel, as reagents in steelmaking (coke), and as structural materials. Charcoal is a less smoky fuel than pyrolyzed wood. Some cities ban, or used to ban, wood fires; when residents only use charcoal (and similarly treated rock coal, called coke) air pollution is significantly reduced. In cities where people do not generally cook or heat with fires, this is not needed. In the mid-20th century, "smokeless" legislation in Europe required cleaner-burning techniques, such as coke fuel and smoke-burning incinerators as an effective measure to reduce air pollution.
== Safety == Theacrine has demonstrated clinical safety and non-habituating effects in healthy humans over eight weeks of daily use at up to 300 mg/day. Moreover, there was no evidence of the tachyphylaxis typical of neuroactive agents like caffeine and other stimulants. In animal studies, theacrine has an LD50 of 810 mg/kg, compared to 265 mg/kg for caffeine.
Sources: en.wikipedia.org
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.
Assay calibration and antibody specificity differ between platforms, so identical samples can yield different numbers. A method change within one laboratory can shift results without any biological change. Cross-validation is often needed for multi-site work.
They capture only one moment in a pulsatile pattern and are strongly influenced by recent activity and meals. Repeated sampling or overnight profiles provide a more representative view. Provocative testing is an alternative when a dynamic response is of interest.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.